**Supplementary Table A.2. Scenario Analysis on a Shorter Time Horizon**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Time horizon | Factor | Camrelizumab | Chemotherapy | Incremental  camrelizumab vs chemotherapy |
| 3 years | QALYs | 0.64 | 0.39 | 0.25 |
|  | LY | 1 | 0.68 | 0.33 |
|  | Costs (US, $) | 5271.17 | 3400.15 | 1871.02 |
|  | ICER, $/QALY |  |  | 7484.09 |
| 5 years | QALYs | 0.72 | 0.43 | 0.29 |
|  | LY | 1.15 | 0.73 | 0.41 |
|  | Costs (US, $) | 5588.50 | 3516.24 | 2072.25 |
|  | ICER, $/QALY |  |  | 7145.70 |
| 7 years | QALYs | 0.78 | 0.45 | 0.33 |
|  | LY | 1.24 | 0.77 | 0.47 |
|  | Costs (US, $) | 5781.94 | 3585.95 | 2195.99 |
|  | ICER, $/QALY |  |  | 6654.51 |

QALYs: quality-adjusted life-years; LY: life years; ICER: incremental cost-effectiveness ratio